Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Latent Tuberculosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doravirine, Rifapentine and Isoniazid Interaction

NCT03886701
View directory record Official record
Conditions
Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
Interventions
Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management

NCT05772065
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
CDC/NTCA guidelines only, LTBI ASSIST and CDC/NTCA guidelines only
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 22, 2026, 12:34 PM EDT
Recruiting No phase listed Observational

Training Protocol on the Natural History of Tuberculosis

NCT01212003
View directory record Official record
Conditions
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis, Extensively Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 12:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?

NCT00756808
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
65 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits

NCT00804713
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
BST, TST, QFT, T-spot
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
2,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 22, 2026, 12:34 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Equivalence Study of Specificity of PPD

NCT01798095
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
Aplisol@ PPD material, Reference Standard
Biological
Lead sponsor
JHP Pharmaceuticals LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 22, 2026, 12:34 PM EDT
Withdrawn No phase listed Observational

Video Based Directly Observed Therapy for Latent TB

NCT03783728
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine 600 mg orally, Isoniazid 900 mg orally, Pyridoxine 50 mg orally
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV

NCT03702049
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
Nurse-led Community Health Worker TBI (RN/CHW TBI) program
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

NCT01404312
View directory record Official record
Conditions
Tuberculosis, HIV Infections
Interventions
Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

Brief Educational Video for Patients Prescribed LTBI Treatment

NCT05412212
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
LTBI video intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 12:34 PM EDT
Recruiting Not applicable Interventional

Economic Incentives and vDOT for Latent Tuberculosis Infection

NCT05022862
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 12:34 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)

NCT01689831
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2.
Biological
Lead sponsor
JHP Pharmaceuticals LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT

NCT01582711
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine
Behavioral · Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

NCT00763295
View directory record Official record
Conditions
Latent Tuberculosis, HIV Infections
Interventions
T-Spot.TB test
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

NCT02771249
View directory record Official record
Conditions
HIV Infected Population With Latent Tuberculosis
Interventions
rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VDOT for Monitoring Adherence to LTBI Treatment

NCT02641106
View directory record Official record
Conditions
Tuberculosis, Latent Tuberculosis Infection
Interventions
Video Directly Observed Therapy, In-Person DOT
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 22, 2026, 12:34 PM EDT
Withdrawn Not applicable Interventional

Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation

NCT00424684
View directory record Official record
Conditions
Chronic Liver Disease, TB
Interventions
collection of blood sample
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000638
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Latent Tuberculosis Infection in Cancer Patients

NCT00507754
View directory record Official record
Conditions
Advanced Cancer
Interventions
T-SPOT TB test
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

NCT01622140
View directory record Official record
Conditions
Latent Tuberculosis Infection, Tuberculosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
21,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 22, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

NCT00023452
View directory record Official record
Conditions
Tuberculosis
Interventions
RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
2 Years and older
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Immune Response to Mycobacterium Tuberculosis Infection

NCT00257907
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 22, 2026, 12:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation of the VIDAS TB-IGRA Assay.

NCT04048018
View directory record Official record
Conditions
Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions
Blood draw and IGRA test
Diagnostic Test
Lead sponsor
BioMérieux
Industry
Eligibility
2 Years and older
Enrollment
2,401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 22, 2026, 12:34 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

NCT04453293
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
BCG (Tokyo 172) vaccine, Placebo
Biological · Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 12:34 PM EDT